Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2021 Jul;13(7):596-600.
doi: 10.1111/1753-0407.13182. Epub 2021 Apr 21.

Do SGLT-2 inhibitors exhibit similar cardiovascular benefit in patients with heart failure with reduced or preserved ejection fraction?

Awadhesh Kumar Singh  1 , Ritu Singh  1 , Anoop Misra  2
Affiliations
Meta-Analysis

Do SGLT-2 inhibitors exhibit similar cardiovascular benefit in patients with heart failure with reduced or preserved ejection fraction?

Awadhesh Kumar Singh et al. J Diabetes. 2021 Jul.

Abstract
in English, Chinese

Highlights The beneficial cardiovascular (CV) effects of SGLT-2 inhibitors (SGLT-2i) in patients with heart failure are already known. Whether SGLT-2i exert similar CV effects in heart failure with reduced or preserved ejection fraction is not known. This meta-analysis showed SGLT-2i exert similar CV benefits irrespective of the types of heart failure. Future trials will confirm or refute the CV effects of SGLT-2i in patients with heart failure with preserved ejection fraction.

SGLT-2抑制剂(SGLT-2i)对心力衰竭患者的心血管有益已为人所知。SGLT-2i在射血分数降低或保持不变的心力衰竭患者中是否具有类似的心血管效应尚不清楚。这项meta分析显示，SGLT-2i与心力衰竭的类型无关，具有相似的心血管益处。未来的试验将证实或驳斥SGLT-2i对射血分数保持不变的心力衰竭患者的心血管效应。.

Keywords: SGLT-2 inhibitors; cardiovascular death; heart failure hospitalization; preserved ejection fraction; reduced ejection fraction.

PubMed Disclaimer

References

REFERENCES

    1. Fitchett D, Butler J, van de Borne P, et al. Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial. Eur Heart J. 2018;39(5):363-370.
    1. Radholm K, Figtree G, Perkovic V, et al. Canagliflozin and heart failure in type 2 diabetes mellitus: results from the CANVAS program. Circulation. 2018;138(5):458-468.
    1. Kato ET, Silverman MG, Mosenzon O, et al. Effect of Dapagliflozin on heart failure and mortality in type 2 diabetes mellitus. Circulation. 2019;139(22):2528-2536.
    1. Cosentino F, Cannon CP, Cherney DZI, et al. Efficacy of Ertugliflozin on heart failure-related events in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease: results of the VERTIS CV trial. Circulation. 2020;142:2205-2215. https://doi.org/10.1161/CIRCULATIONAHA.120.050255.
    1. Sarraju A, Li J, Cannon CP, et al. Canagliflozin reduces cardiovascular and renal events independent of baseline heart failure: a credence secondary analysis. J Am Coll Cardiol. 2020;75(11):1018.

MeSH terms

Substances

LinkOut - more resources